Pluri Inc Stock Price, News & Analysis

Pluri (NASDAQ, TASE: PLUR) launched a wholly-owned subsidiary, Cellav Health and Aesthetics, to commercialize exosome-enhanced regenerative skincare using Pluri’s proprietary 3D cell expansion platform.

Pluri announced a commercial collaboration with Miss Universe Skincare to co-develop a line of cell-based skincare products, with the first product expected to launch in the first half of 2026 and be distributed via Miss Universe Skincare’s global platform. The collaboration will be presented during pre-gala activities of the 74th Miss Universe event in Thailand. Management describes the move as part of Pluri’s strategy to enter high-growth, revenue-generating beauty markets.

Pluri (NASDAQ, TASE: PLUR) announced on November 10, 2025 a series of international strategic collaborations across Asia, Europe and the U.S. through its subsidiaries Ever After Foods, Kokomodo and Coffeesai to advance cultivated meat, cultivated cacao and cell-based coffee.

Each collaboration is anchored by a collaborator-funded minimum-viable-product (MVP) / proof-of-concept to support scale-up validation, pre-commercial trials and pilot results, with near-term milestones focused on pilot readouts and expansion of collaborator programs in priority markets.

Pluri (NASDAQ/TASE: PLUR) subsidiary Coffeesai signed a collaboration with the Instituto del Café de Chiapas on Oct 8, 2025 to advance cell-based coffee manufacturing in Chiapas, Mexico. The agreement establishes a three-phase roadmap: cell line development, pilot-scale 3D bioreactor biofarming in Chiapas, and evaluation of commercial-scale manufacturing subject to definitive agreements and approvals. The partnership aims for non-dilutive license and technology-transfer revenues, royalty-bearing models and joint ventures to access the >$250B global coffee market. Coffeesai will begin Phase 1 immediately to validate cell lines, then deploy pilot-scale operations to test scalability and process robustness.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) has signed a Letter of Intent with Minaris Advanced Therapies for manufacturing NurOwn®, its adult stem cell therapy for ALS treatment. The partnership will facilitate technology transfer and clinical trial manufacturing at Minaris' Allendale, New Jersey facility in preparation for BrainStorm's planned Phase 3b clinical trial.

This U.S.-based manufacturing collaboration complements BrainStorm's recent partnership with Pluri Inc. (Nasdaq: PLUR) in Israel, establishing a robust manufacturing network for NurOwn®. The strategic relationship aims to advance the clinical development of this therapy for ALS patients through a multicenter Phase 3b trial.

Pluri Inc. (PLUR) reported significant growth and strategic developments in its fiscal year 2025. The company achieved nearly 400% revenue growth in the first nine months, reaching $938,000 compared to $230,000 in the same period last year, driven by CDMO and AgTech businesses. Pluri is expanding into the cultivated cacao and coffee markets to address supply chain challenges caused by climate change and rising demand. The company maintains a 69% stake in Ever After Foods, which secured a $10 million funding round led by strategic partners. While NIH and DoD funding for PLX-R18 development was discontinued, Pluri partnered with Hemafund for nuclear emergency response plans. The company is actively pursuing partnerships in the cocoa and coffee industries, focusing on commercial implementation and potential technology licensing opportunities.

Pluri Inc. (PLUR) has completed the acquisition of approximately 71% stake in Kokomodo , a cultivated cacao AgFoodTech company, for $4.5 million paid in 976,139 Common Shares. The strategic acquisition combines Pluri's mass-scale cell production expertise with Kokomodo's cellular agriculture technology for creating climate-resilient cacao.

Kokomodo will continue operating independently as a Pluri subsidiary, maintaining its mission, team, and brand identity under CEO Tal Govrin's leadership. The acquisition aims to accelerate Kokomodo's production capabilities and global expansion while addressing sustainability challenges in the cacao industry.

The global cacao market, valued at $13.5 billion in 2023, is projected to grow at a CAGR of 8.2% to reach $23.5 billion by 2030.

DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.

Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.

Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.

Pluri Inc. (PLUR) has strengthened its intellectual property portfolio with two new patents for 3D expansion of immune cells, granted by the USPTO and Israel. The patents specifically cover MAIT (Mucosal-Associated Invariant T) cell expansion technologies in large-scale bioreactors.

The company's placental MAIT cells platform aims to address solid tumor treatment, targeting the immune cell engineering market (projected at $11.7B by 2030) and cancer immunotherapy market ($136B in 2025). These cells offer unique advantages over conventional T cells, including lower alloreactivity and enhanced tumor-targeting capabilities.

Pluri's IP estate now encompasses over 250 patents pending, allowed, and granted. The technology enables commercial-scale production of 'off-the-shelf' immune cell therapies, with applications extending to Tumor Infiltrating Lymphocytes (TILs).

Pluri Inc. (PLUR) has signed an exclusive collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness. The three-year partnership focuses on stockpiling and distributing Pluri's PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS).

The collaboration aims to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals. If successful, the initiative could generate over $100 million in value for both parties. Hemafund will leverage its biobank infrastructure for storage and distribution across Ukraine.

This strategic initiative comes in response to recent security concerns, including a Russian drone strike on the Chernobyl nuclear power plant. The partnership encompasses:

• Secure storage and distribution systems
• Regulatory compliance support
• Clinical advancement opportunities
• Public and private funding initiatives